Professor John Sjögren new board member of Orexo AB

At Orexo’s Annual General Meeting on April 20, 2005, Professor John Sjögren was elected new member of the Board of Directors. John Sjögren has many years of experience in drug development within Astra Hässle and unique knowledge in pharmaceutics – the science of the delivery of pharmaceutical substances for the most effective therapeutic impact.

“Orexo’s successes are built on a combination of creativity, expertise and the ability to deliver,” says Zsolt Lavotha, President and CEO, Orexo AB. “This is a description that also fits Professor Sjögren very well and it is particularly pleasing that we can link his experience and expertise to the company at a time when Orexo’s pace of development and expansion is high.” During the years 1973-1999, John Sjögren served as Adjunct Professor in Industrial Pharmacy at the department of Pharmaceutics at Uppsala University. During 1959-1994, he held various executive positions for Astra Hässle’s pharmaceutical research and was a member of the company’s management group from 1984 through 1998. Professor John Sjögren has conducted internationally renowned research in the areas of pharmaceutic technology and biopharmaceutics, that is, how drug substances are assimilated and distributed in the body. He has particularly studied tablet formulation processes and technical properties of excipients as well as the formulation principles and biopharmaceutic methodology for evaluation of tablet preparations. Professor Christer Nyström, one of Orexo’s founders and Board members since 1995, resigned from the Board. For further information, please contact: Zsolt Lavotha, President & CEO, Orexo AB +46 (0)18 780 88 00. E-mail: zsolt.lavotha@orexo.se Johan Tamsen, Corporate Communications +46 (0)733 25 40 10, E-mail: johan.tamsen@orexo.se

About Us

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 845 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

Subscribe

Documents & Links